Moxifloxacin exhibits concentration-dependent prolongation of human QTc intervals and bactericidal activity againstMycobacterium tuberculosisHowever, moxifloxacin plasma concentrations are variable between patients. We evaluated whether human gene polymorphisms affect moxifloxacin plasma concentrations in tuberculosis patients from two geographic regions. We enrolled a convenience sample of 49 adults with drug-sensitive pulmonary tuberculosis from Africa and the United State s enrolled in two treatment trials of moxifloxacin as part of multidrug therapy. Pharmacokinetic parameters were evaluated by noncompartmental techniques. Human single-nucleotide polymorphisms of transporter genes were evaluated with analysis of covariance on moxifloxacin exposure and peak concentration (Cmax). Moxifloxacin area under the concentration-time curve from 0 to 24 h (AUC0-24) and Cmaxwere significantly increased by drug mg/kg dosage and genotype of variant g.-11187G>A in theSLCO1B1gene (rs4149015), but not by geographic region. Median moxifloxacin AUC0-24was 46% higher and Cmax30% higher in 4 (8% of) participants who had theSLCO1B1g.-11187 AG genotype compared with 45 participants who had the wild type GG genotype (median from model, AUC0-2434.4 vs. 23.6 μg*h/mL,P=.005; Cmax3.5 vs. 2.7 μg/mL,P=.009, ANCOVA). Because moxifloxacin exhibits concentration-dependent prolongation of human QTc intervals, and prolonged QTc intervals are associated with cardiac arrhythmia, further study is needed to evaluate risk associated with theSLCO1B1g.-11187G>A variant.